Literature DB >> 1905810

Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate.

H Okada1, Y Inoue, T Heya, H Ueno, Y Ogawa, H Toguchi.   

Abstract

The pharmacokinetic parameters of leuprolide acetate, a potent analogue of LH-RH, were determined in rats and dogs after i.v. and s.c. dosing with leuprolide solution. The effective human dose of once-a-month injectable microspheres of leuprolide was estimated to be about 3.2 to 8.1 mg analogue/month using these parameters. After microsphere injection at three different doses in rat serum leuprolide concentrations were sustained for over 4 weeks, and the AUCs and mean serum levels were linearly correlated with the dose. The serum levels and urinary excretion of the analogue in rats after repeated s.c. injection of the microspheres every 4 weeks exhibited similar profiles after each injection; no changes of the absorption and excretion of the analogue after the repeated injection could be demonstrated. The serum levels of the analogue metabolite (M-I) were 21% of the intact form 3 hr after injection of the microspheres but very low at the steady state after 1 to 4 weeks.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905810     DOI: 10.1023/a:1015818504906

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate.

Authors:  H Okada; T Heya; Y Ogawa; H Toguchi; T Shimamoto
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

2.  High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite.

Authors:  H Ueno; S Matsuo
Journal:  J Chromatogr       Date:  1991-05-03

3.  Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group.

Authors:  R Sharifi; M Soloway
Journal:  J Urol       Date:  1990-01       Impact factor: 7.450

4.  Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration.

Authors:  L T Sennello; R A Finley; S Y Chu; C Jagst; D Max; D E Rollins; K G Tolman
Journal:  J Pharm Sci       Date:  1986-02       Impact factor: 3.534

5.  Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals.

Authors:  Y Ogawa; H Okada; T Heya; T Shimamoto
Journal:  J Pharm Pharmacol       Date:  1989-07       Impact factor: 3.765

6.  A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid.

Authors:  Y Ogawa; M Yamamoto; H Okada; T Yashiki; T Shimamoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1988-03       Impact factor: 1.645

7.  One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.

Authors:  H Okada; T Heya; Y Ogawa; T Shimamoto
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

8.  Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropin responses by radioimmunoassay.

Authors:  H Okada; I Yamazaki; T Yashiki; T Shimamoto; H Mima
Journal:  J Pharm Sci       Date:  1984-03       Impact factor: 3.534

9.  Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Authors: 
Journal:  N Engl J Med       Date:  1984-11-15       Impact factor: 91.245

10.  Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.

Authors:  H Okada; Y Sakura; H Kawaji; T Yashiki; H Mima
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

  10 in total
  19 in total

1.  Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen.

Authors:  B Baras; M A Benoit; L Dupré; O Poulain-Godefroy; A M Schacht; A Capron; J Gillard; G Riveau
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres.

Authors:  Byung Ho Woo; Kyu-Heum Na; Bhas A Dani; Ge Jiang; B C Thanoo; Patrick P DeLuca
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of depot leuprorelin.

Authors:  Piero Periti; Teresita Mazzei; Enrico Mini
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone.

Authors:  Yilmaz Capan; Ge Jiang; Stefano Giovagnoli; Kyu-Heum Na; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

5.  Preparation and characterization of a composite PLGA and poly(acryloyl hydroxyethyl starch) microsphere system for protein delivery.

Authors:  B H Woo; G Jiang; Y W Jo; P P DeLuca
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

6.  A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.

Authors:  Chay Ngee Lim; Ahmed Hamed Salem
Journal:  Clin Pharmacokinet       Date:  2015-09       Impact factor: 6.447

7.  Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs.

Authors:  M Schwahn; N V Nagaraja; H Derendorf
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

8.  Formulation and performance characterization of radio-sterilized "progestin-only" microparticles intended for contraception.

Authors:  Shivanand Puthli; Pradeep Vavia
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

9.  Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant.

Authors:  H B Ravivarapu; K L Moyer; R L Dunn
Journal:  AAPS PharmSciTech       Date:  2000-02-28       Impact factor: 3.246

10.  Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.

Authors:  H Okada; Y Doken; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.